United States

People: Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

18 Sep 2017
Change (% chg)

$0.08 (+0.10%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lundberg, Jan 

Dr. Jan M. Lundberg Ph.D., is Executive Vice President - Science and Technology, President - Lilly Research Laboratories of the Company. He has a Ph.D. from Sweden's Karolinska Institute, where he was a professor in the department of pharmacology before moving to industry. Prior to Karolinska, he attended Gustavus Adolphus College in Minnesota and the University of Gothenburg in Sweden. He has been a member of the Swedish Medical Research Council and of the Advisory Board for Drug Approvals at the Swedish Medical Product Agency. In January 2003, he was appointed Honorary Doctor of Pharmacy at Uppsala University. During the last 10 years at AstraZeneca, as head of global discovery research, he was instrumental in delivering 150 drug candidates to the company's pipeline. He had a role in external activities, including in-licensing of projects and technologies, as well as acquisitions of biotech companies. His organization was with both small molecules and biologics. For the past seven years, he has been an executive vice president and member of the senior executive team, reporting to the CEO of AstraZeneca.

Basic Compensation

Total Annual Compensation, USD 2,187,040
Restricted Stock Awards, USD 3,600,000
Long-Term Incentive Plans, USD --
All Other, USD 687,852
Fiscal Year Total, USD 6,474,900

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --